Case todayStrengtheningAnalyst upgradeThe case · mixed · Oct 15, 2026Own ANNX if its complement/C1q pipeline produces de-risking clinical or regulatory events before financing needs dilute away the upside.5 conditions1 strengthening · 3 holding · 1 weakeningNext resultsFeb 8, 2027Projected from its filing dates

ANNX at a glance

The past year

Chart

−23.6% $3.10, close Nov 20

From the highest close
−55.5%
Vs the 200-day average
−38.4%
Nov 19, 2025Daily close, AnnexonNov 20, 2026

Short interest

History

29.0M shares

Of shares outstanding
15.2%
Since the last report
−8.4%
Days to cover
7.2 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

$121,720 bought on the open market

Purchases
1
Form 4s filed
Nov 15 – Nov 21

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

ANNX price history

Latest price$3.10Today−$0.31 (-9.09%)
ANNX -21.82%S&P 500 -10.82%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Annexon's platform must show that targeted complement/C1q inhibition produces differentiated clinical benefit or safety versus broader complement and immunology alternatives; without that, the company has little durable pricing power or partner leverage.HoldingMateriality: High

    GAAP annual operating loss was $216.4 million in FY2025, showing substantial ongoing investment in development capacity. If the biology is validated, losses are investment in a scarce drug asset; if not, operating spend is value-destructive burn.

    Watch: A lead program fails a pivotal or registrational trial endpoint or shows a safety signal that undermines chronic or acute use.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating loss was $216.4 million in FY2025, showing substantial ongoing investment in development capacity.

    Open source ↗
  • Annexon's clinical optionality depends on its cash lasting until value-creating data or regulatory milestones, because a forced financing before de-risking would shift upside from existing holders to new capital.HoldingMateriality: High

    Cash was $162.1 million at December 31, 2025, up from $49.5 million at December 31, 2024. Adequate runway lets shareholders own the catalyst; insufficient runway turns even good science into a dilution problem.

    Watch: A regulator asks for additional studies or longer follow-up, extending the time and cost to the next approval-relevant milestone.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $162.1 million at December 31, 2025, up from $49.5 million at December 31, 2024.

    Open source ↗
  • Management must convert rising cash burn into nearer-term registrational or regulatory de-risking rather than open-ended platform expansion; otherwise scale works against shareholders.WeakeningMateriality: Medium

    GAAP annual operating cash flow was negative $186.4 million in FY2025, compared with negative $118.0 million in FY2024. The owner benefits only if each incremental dollar of burn increases approval probability or asset value; unfocused spend shortens runway without improving odds.

    Watch: The company starts multiple large trials before a lead program has produced decisive de-risking data.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was negative $186.4 million in FY2025, compared with negative $118.0 million in FY2024.

    Open source ↗
  • Annexon's small specialist operating model must remain an advantage by outsourcing or partnering capital-intensive functions until approval is closer; a premature commercial or manufacturing buildout would reduce financial flexibility.HoldingMateriality: Medium

    The profile reports 96 employees, indicating a relatively small organization for a public drug developer. A lean model preserves option value in a binary biotech; a fixed-cost buildout raises the break-even hurdle before the product risk is resolved.

    Watch: The company begins a large commercial hiring campaign before approval probability and launch timing are substantially de-risked.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    The profile reports 96 employees, indicating a relatively small organization for a public drug developer.

    Open source ↗
  • Low balance-sheet leverage preserves strategic optionality while the pipeline is still binary; restrictive debt, royalty, or liability growth would transfer part of the upside away from common shareholders.StrengtheningMateriality: Medium

    Liabilities were $65.9 million at December 31, 2025, compared with assets of $277.6 million. If positive data arrive, a clean balance sheet lets equity holders capture more of the re-rating; if obligations rise, the upside is shared with creditors or royalty holders.

    Watch: The company raises capital through restrictive debt or royalty financing tied to future product economics.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Liabilities were $65.9 million at December 31, 2025, compared with assets of $277.6 million.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Annexon's platform must show that targeted complement/C1q inhibition produces differentiated clinical benefit or safety versus broader complement and immunology alternatives; without that, the company has little durable pricing power or partner leverage. If the biology is validated, losses are investment in a scarce drug asset; if not, operating spend is value-destructive burn.

Annexon's clinical optionality depends on its cash lasting until value-creating data or regulatory milestones, because a forced financing before de-risking would shift upside from existing holders to new capital. Adequate runway lets shareholders own the catalyst; insufficient runway turns even good science into a dilution problem.

Management must convert rising cash burn into nearer-term registrational or regulatory de-risking rather than open-ended platform expansion; otherwise scale works against shareholders. The owner benefits only if each incremental dollar of burn increases approval probability or asset value; unfocused spend shortens runway without improving odds.

Annexon's small specialist operating model must remain an advantage by outsourcing or partnering capital-intensive functions until approval is closer; a premature commercial or manufacturing buildout would reduce financial flexibility. A lean model preserves option value in a binary biotech; a fixed-cost buildout raises the break-even hurdle before the product risk is resolved.

Low balance-sheet leverage preserves strategic optionality while the pipeline is still binary; restrictive debt, royalty, or liability growth would transfer part of the upside away from common shareholders. If positive data arrive, a clean balance sheet lets equity holders capture more of the re-rating; if obligations rise, the upside is shared with creditors or royalty holders.

All standing thesis claims
Original report summary

its complement/C1q pipeline produces de-risking clinical or regulatory events before financing needs dilute away the upside.

Evidence assessed Oct 15, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Annexon

Where the evidence on Annexon disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 1 strengthening, 3 holding and 1 weakening.

Bull case: what the evidence supports

  • Annexon's platform must show that targeted complement/C1q inhibition produces differentiated clinical benefit or safety versus broader complement and immunology alternatives; without that, the company has little durable pricing power or partner leverage.

    sec.gov ↗

  • Annexon's clinical optionality depends on its cash lasting until value-creating data or regulatory milestones, because a forced financing before de-risking would shift upside from existing holders to new capital.

    sec.gov ↗

  • Annexon's small specialist operating model must remain an advantage by outsourcing or partnering capital-intensive functions until approval is closer; a premature commercial or manufacturing buildout would reduce financial flexibility.

    sec.gov ↗

  • Low balance-sheet leverage preserves strategic optionality while the pipeline is still binary; restrictive debt, royalty, or liability growth would transfer part of the upside away from common shareholders.

    sec.gov ↗

Bear case: what the evidence questions

  • Management must convert rising cash burn into nearer-term registrational or regulatory de-risking rather than open-ended platform expansion; otherwise scale works against shareholders.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Annexon

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Annexon’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Annexon filed an SEC 8-K on 2026-08-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Director or principal officer change.

    Annexon filed an SEC 8-K on 2026-08-10: Director or principal officer change. It is a dated development that tests the current thesis.

  3. Mixed
    Other material event.

    Annexon filed an SEC 8-K on 2026-08-06: Other material event. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A lead program fails a pivotal or registrational trial endpoint or shows a safety signal that undermines chronic or acute use.
  • A regulator asks for additional studies or longer follow-up, extending the time and cost to the next approval-relevant milestone.
  • The company starts multiple large trials before a lead program has produced decisive de-risking data.
  • The company begins a large commercial hiring campaign before approval probability and launch timing are substantially de-risked.
  • The company raises capital through restrictive debt or royalty financing tied to future product economics.

ANNX news

Loading headlines…

Financial statements

ANNX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

ANNX: quick answers

When does Annexon (ANNX) report earnings next?
Annexon's next results are projected for February 8, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 9, 2026. Earnings calendar
What is ANNX's short interest?
As of October 30, 2026, 29.0M ANNX shares were sold short, 15.2% of its shares outstanding, down 8.4% from the count before. At the stock's average daily volume that is 7.2 days to cover. FINRA publishes the count twice a month. ANNX short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.